[Immunobiology of bovine respiratory syncytial virus infections].

This paper describes recent findings on the immunobiology of bovine respiratory syncytial virus (BRSV) infections. The pathobiology of alveolar macrophages and BRSV, and the immunological reaction of cattle to the virus after natural or experimental infection, or vaccination, were studied. Because in severe cases BRSV infection leads to lower respiratory tract disease, replication of BRSV in alveolar macrophages was studied. Alveolar macrophages, which are important aspecific defense cells in the lower respiratory tract, exhibited a high intrinsic resistance to BRSV. Furthermore, BRSV-infected alveolar macrophages produced significantly less nitric oxide (which has a bacteriocidal effect) than uninfected macrophages. The kinetics of antibody titres against the envelope protein G were different from those of antibody titres against the envelope protein F. For example, many animals that are reinfected do not possess antibodies against the G protein. After vaccination or after natural infection, antibody titres against the F and G protein, and against epitopes on the F protein, differed markedly, and also in animals with different MHC haplotypes. These findings may be related to differences in protection. The strains of BRSV that circulate in the Netherlands belong to the subgroups A and AB. There was no evidence for differences in virulence between these subgroups. BRSV could be detected in 30% of lungs obtained from calves suffering from severe lower respiratory tract disease. Based on cross-protection studies, calves that were infected with a virus from a particular BRSV subgroup were protected against reinfection with a virus from a different subgroup. A recombinant gE-protein negative bovine herpesvirus 1 vaccine carrying a gene encoding the G protein of BRSV, and a DNA vaccine encoding the same protein afforded protection after experimental challenge of calves. This offers the possibility to develop effective multivalent (gE-negative BHV1) marker vaccines in the future.